MODULE 3: Advances in safety in the treatment of PCa

Prof. Dr. A.S. Merseburger (DE)
Dr. A. So (CA)
Ass. Prof. K Zhang (US)
Date & time
Wednesday, 1 September 2021, 18:30 - 19:30 CEST

MODULE 3: Advances in safety in the treatment of PCa

Pre-recording by Dr. Alan So - CUA
Safety data - GNRH Analogues, focus on CVD risk profile 
- PCa therapy induced CVD toxicity
- ADT plus newer antiandrogens
- Radiotherapy alone or in combination
- Data from latest trials – HERO

Pre-recording by Prof. Axel Merseburger - EAU
Safety data – mHSPC therapy and CVD risk profile
- Data from animal models & basic research
- Other treatment modalities (chemotherapy, surgery, ADT alone or in combination)                                       
- New treatment modalities and CVD toxicity

Live webinar 
Case study (incl Cardiac biomarkers) by Ass. Prof. Katie Zhang - ICOS
Q&A by panellists Dr. Alan So & Prof. Axel Merseburger

At a glance
Publication date: September 2021
Available languages: English
Topic: Prostate Cancer
CME: This webinar is accredited with 1 European CME credit (ECMEC®) upon completion of the questionnaire after attending the live webinar
Duration: Approx. 60  minutes

This educational activity has been funded by Ferring Pharmaceutical. The educational programme of this online activity has been a collaboration with Ferring Pharmaceutical, but independently developed and approved by the Canadian Urological Association, the International Cardio-Oncology Society together with the European Association of Urology

Registration for this webinar is now closed

The recording will be available at 24 hours after the webinar has taken place.

Back to UROwebinar overview
Contact information
European Association of Urology
Registration Department
+31 (0)26 389 1751